4.24BMarket Cap-101000P/E (TTM)
64.670High64.560Low1.33MVolume64.600Open64.600Pre Close86.06MTurnover3.42%Turnover RatioLossP/E (Static)65.56MShares64.72052wk High12.92P/B2.52BFloat Cap8.11052wk Low--Dividend TTM38.91MShs Float81.720Historical High--Div YieldTTM0.17%Amplitude2.050Historical Low64.601Avg Price1Lot Size
Alpine Immune Stock Forum
🤩🤩🤩 SELL ALL IN APRIL AND TRAVEL (+ 💰💰💰💰💰) THEN SELL ALL AGAIN IN MAY (- $$$$$$ ) AND RUN AWAY 😭😭😭
47. G = Make Money From Thin Air, Block Short, Keep Repeating (Pump and Drop) to trap Buyers or Create Fake Symbols to Rob Money From Investors
47. T = Track and Kill by Weapons, Dark Magics, Nightmare, Accident, Sickness, Burn, Drown....them, and kill their children too, if they teach their children the same
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US)$ unveiled plans to buy biotech $Alpine Immune(ALPN.US)$ for $4.9 ...
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US)$
$Johnson & Johnson(JNJ.US)$ to acquire $ShockWave Medical(SWAV.US)$
$Vertex Pharmaceuticals(VRTX.US)$ to acquire $Alpine Immune(ALPN.US)$
What companies will be next? 🤔
Gapping up
$Nike(NKE.US)$ stock increased by 1.4% after the sportswear company revealed its Olympic kits, aiming to leverage the appeal of top athletes to attract more consumers.
$Alpine Immune(ALPN.US)$ stock surged over 36% after Vertex Pharmaceuticals announced its plan to acquire the biotech company for about $4.9 billion in cash, which would give Vertex access to a treatment for an autoimmune kidney disease.
$Rent the Runway(RENT.US)$ stock ju...
⚡ Vertex buys Alpine in a $4.9B deal 💰
⇨ Acquisition for $65/sh or $4.9B in cash 🤑
▪ Transaction closes in Q2 2024
⇨ Includes ALPN lead product, povetacicep (ALPN-303)
▪ best-in-class potential in patients with IgA nephropathy
▪ Ph3 to initiate in H2 2024
No comment yet